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Objective. To examine the effects of yoga versus an educational film program on sleep, mood, perceived stress, and sympathetic
activation in older women with RLS. Methods. Participants were drawn from a larger trial regarding the effects of yoga on
cardiovascular disease risk profiles in overweight, sedentary postmenopausal women. Seventy-five women were randomized to
receive either an 8-week yoga (n = 38) or educational film (n = 37) program. All 75 participants completed an RLS screening
questionnaire. The 20 women who met all four diagnostic criteria for RLS (n = 10 yoga, 10 film group) comprised the population
for this nested study. Main outcomes assessed pre- and post-treatment included: sleep (Pittsburgh Sleep Quality Index), stress
(Perceived Stress Scale), mood (Profile of Mood States, State-Trait Anxiety Inventory), blood pressure, and heart rate. Results.
The yoga group demonstrated significantly greater improvements than controls in multiple domains of sleep quality and mood,
and significantly greater reductions in insomnia prevalence, anxiety, perceived stress, and blood pressure (all P’s≤ 0.05). Adjusted
intergroup effect sizes for psychosocial variables were large, ranging from 1.9 for state anxiety to 2.6 for sleep quality. Conclusions.
These preliminary findings suggest yoga may offer an effective intervention for improving sleep, mood, perceived stress, and blood
pressure in older women with RLS.
1. Introduction
Restless legs syndrome (RLS) is a distressing and potentially
debilitating sleep disorder, affecting up to 29% of U.S.
and European general adult populations, and an estimated
average of 19.5% of primary care patients [1]. RLS is
characterized by a compelling urge to move the legs, usually
accompanied by uncomfortable sensations in the legs, that:
begins or worsens during periods of inactivity, is worse
during the evening and nighttime hours, and is partially
or totally relieved by movement [2]. Prevalence increases
with age, and RLS is approximately twice as common in
women as in men [1]. RLS has been repeatedly associated
with significant reductions in quality of life comparable to
or worse than those reported in Parkinson’s disease, diabetes,
stroke, and other serious chronic disorders [3–7]. RLS has
also been linked to substantial impairment in sleep, mood,
and health and is associated with significant societal and
economic burden [4, 5, 7].
While RLS is considered a neurological disorder, the
etiology of RLS remains poorly understood [8–10]. Defects
in dopamine function and iron metabolism have been
considered key factors in the pathogenesis of RLS for decades
[11–14], based largely on clinical observations [14–18],
although evidence remains inconclusive [8, 15, 19, 20]. An
emerging body of evidence supports a potential role for
autonomic and metabolic dysfunction. Recent studies have
linked RLS to cardiovascular disease (CVD), as well as
to key components of the metabolic syndrome, including
diabetes, obesity, hypertension, and dyslipidemia, conditions
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associated with both autonomic and metabolic dysregu-
lation [21]. RLS is characterized by elevated nocturnal
blood pressure and heart rate [22–24], increased nocturnal
hypothalamic-pituitary-adrenal (HPA) axis activation [25],
elevated sympathetic activation, and reduced parasympa-
thetic tone [26, 27], suggesting that autonomic and HPA
axis dysfunction may in part underlie the development
and/or progression of RLS and could help explain the
observed association of RLS to CVD and related disorders
[21].
There is no cure for RLS. Existing treatments are
aimed at symptom reduction and include dopaminergic
agents, opioids, sedative hypnotics, anticonvulsants, and
benzodiazepines. Unfortunately, these medications can have
serious side effects. For example, common side effects of
dopaminergic agents, considered the first-line pharmaco-
logic treatment for RLS sufferers [4, 16, 28], include rebound
and augmentation of symptoms, dyskinesia, nausea and
vomiting, hypotension, impulse control disorders, dizziness,
and insomnia or drowsiness [7, 29–31]; common side effects
of other RLS medications include potential for dependence,
confusion, blurred vision, coordination problems, and other
adverse sequellae [7, 29, 30]. These effects can be particularly
problematic in older populations [32, 33], who also suffer
disproportionately from RLS [29, 34]. In addition, the
benefits of these medications may diminish over time [35,
36], leaving patients with few treatment options.
Given the substantial drawbacks of these pharmaco-
logic treatments, investigation of safe, nonpharmacologic
therapies that address apparent underlying risk factors is
needed. Yet research remains very sparse. For example, there
have to date been only three small trials examining the
potential benefits of lifestyle or behavioral interventions
for individuals suffering from RLS. These include two
studies evaluating the effects of a 12–16 week exercise
program versus usual care on RLS symptoms [37, 38],
and a recent pre-post trial assessing the effects of cognitive
behavioral therapy (CBT) in adults with primary RLS and
mild-moderate psychosocial impairment [39]. Investigators
reported significant improvements in RLS-related outcomes
relative to the control group [37, 38] or baseline [39],
suggesting that nonpharmacologic interventions may benefit
those suffering from RLS.
Yoga, an ancient mind-body discipline that is increas-
ingly popular in the U.S. [40], may represent a particularly
promising nonpharmacologic therapy for RLS. Accumulat-
ing evidence from controlled trials suggests yoga can reduce
blood pressure [41], improve glucose tolerance [41–43],
lipid profiles [41, 44, 45], body composition [41, 45], and
autonomic function [42, 44, 45], enhance mood [46–49],
and improve sleep [48, 50, 51], factors linked to both RLS and
CVD risk [8, 9, 16, 21]. In addition, studies suggest yoga can
decrease muscular excitability and induce more rapid muscle
relaxation [52], factors that have also been implicated in RLS
[53, 54]. However, while yoga and other relaxation therapies
are often recommended for RLS patients [55, 56], clinical
trials are lacking. In this small, nested RCT, we investigated
the effects of yoga on sleep, mood, stress, and associated
outcomes in older women with RLS.
2. Methods
Participants for this study were drawn from a feasibility
study regarding the effects of yoga on CVD risk profiles in
sedentary, overweight postmenopausal women [57]. In this
larger RCT, 75 women aged 45–79 years were recruited from
the community using a combination of flyers, brochures,
and newspaper advertisements. Eligible participants were
nonsmoking women at least 45 years of age who were post-
menopausal (≥12 months amenorrheic), physically inactive
(exercising less than 20 minutes, 3 times per week), and over-
weight (body mass index (BMI, calculated as kg/m2) ≥25,
and/or waist circumference ≥88 cm) or had a first-degree
relative with diabetes or essential hypertension. Excluded
were women who had practiced yoga within the last year, had
uncontrolled hypertension, had been diagnosed with sleep
apnea or with diabetes, cancer, heart failure, or other serious
chronic disorders, or had any orthopedic, neurological,
or other condition that might prevent them from safely
completing an 8-week yoga program. Following enrollment,
screening, and baseline assessment, eligible participants were
randomized, using a computer-generated randomization list
provided by a statistician not associated with the study, to
receive either a gentle 8-week yoga program (n = 38) or an
8-week educational film program (n = 37). Each participant
was administered her treatment assignment sequentially in
order of enrollment, via coded opaque envelopes containing
general study instructional materials, a welcome letter, and
information pertinent to the yoga or educational film pro-
gram. The study was approved by the University of Virginia
Health Sciences Research Institutional Review Board, and
all participants provided informed consent prior to study
enrollment.
2.1. RLS andOutcome Assessment. Participants completed an
RLS screening questionnaire at baseline. The questionnaire
was adapted by the authors from the Athens Sleep Center
Screening Questionnaire for RLS (http://www.athenssleep-
center.com/PDF/AScreeningQuestionaireRLS.pdf) to incor-
porate the established four criteria for RLS established by the
International Restless Legs Syndrome Study Group (IRLSSG)
[2]. Participants were asked if they ever experienced an
urge to move with uncomfortable/funny (e.g., tingling,
creeping, crawling) sensations in the legs, and if these
feelings began or worsened when lying or sitting, were worse
in the evening/night, and were relieved at least in part
by movement (e.g., wiggling feet, toes, or walking). The
questionnaire also included an item regarding frequency of
symptoms (never, occasionally (<1x/month), sometimes (1–
3x/month), frequently (1-2x/week to daily), or only in the
past). Those participants endorsing all 4 diagnostic criteria
and reporting symptoms at least once per month (N = 20)
were considered to meet diagnostic criteria for RLS and were
included in the present study.
Participants underwent a comprehensive assessment at
baseline and following the 8-week intervention period.
All assessments were conducted by experienced General
Clinical Research Center and university clinical laboratory
staff blinded to participant treatment assignment. Detailed
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baseline information was gathered on medical history,
demographic characteristics, and lifestyle factors. Primary
outcomes for this substudy included well-validated self-
report measures of sleep (Pittsburgh Sleep Quality Index
(PSQI)) [58], stress (Perceived Stress Scale (PSS)) [59], mood
(Profile of Mood States (POMS)) [60], and anxiety (State-
Trait Anxiety Inventory (STAI)) [61], as well as indices of
sympathetic activation (blood pressure, heart rate). Clinical
insomnia was defined as a score of greater than 5 on the
PSQI [58, 62]. Blood pressure and heart rate were measured
in a supine position following a 5-minute rest period;
measurements were taken 3 times and averaged for a final
score.
Additional outcomes included indices of abdominal
adiposity (waist circumference (cm) and BMI (kg/m2)).
At baseline, all women were screened for prediabetes
(fasting glucose 100–125mg/dL)/diabetes (fasting glucose
≥126mg/dL), and serum levels of ferritin were measured.
Blood samples were collected in the morning following an
overnight fast and drawn by a trained phlebotomist using
Vacutainer tubes. Blood samples (ferritin) were stored at
−70◦C until assay. Glucose was assessed using a Beckman
glucose analyzer. Ferritin levels were measured using the
ARCHITECT ferritin assay, a ChemiluminescentMicroparti-
cle Immunoassay (CMIA) for the quantitative determination
of ferritin in human serum and plasma.
To assess the possible influence of physical activity
and social support on change in outcomes over time,
factors implicated in RLS [63] and strongly linked to both
sleep and mood [64], participants completed the Physical
Activity Scale for the Elderly (PASE) [65] and the Duke
Social Support Index (abbreviated form [66]) pre- and
posttreatment. To measure expectations of benefit, a brief
treatment expectancy questionnaire was also administered
to all participants. In addition, all subjects were asked to
complete a short, anonymous exit questionnaire regarding
their experience with the study.
2.2. Intervention. Each group (yoga and film intervention)
attended a 90-minute class twice weekly for 8 weeks. Classes
for the two programs were scheduled at the same times and
in similar settings. Class size in both groups was limited to
no more than 14 participants. Upon completing the study,
all participants were given $150 for their time and travel
expenses. Film group participants also received the yoga
home practice materials, as well as coupons to attend local
Iyengar yoga classes. Similarly, yoga group participants were
also offered the opportunity to view the educational films
following completion of the final assessment.
2.2.1. Yoga Intervention. Participants randomized to the yoga
program completed a gentle Iyengar yoga program specif-
ically designed for older, sedentary adults. In addition to
attending classes, participants were asked to complete at
least 30 minutes of home practice on nonclass days, with
the aid of a DVD and a booklet illustrating the yoga home
practice routines. Designed and taught by a senior Iyengar
yoga instructor with over 30 years of experience, the yoga
program included the following 23 active and restorative
poses (asanas): Mountain (Tadasana and Urdhva hastasana
in Tadasana); Standing wide apart legs (Prasarita padotta-
nasana); Warrior I and II (Virabhadrasana I and II); Fierce
or chair pose (Utkatasana); Extended hands and feet
pose (Utthita hasta padasana); 1/2 forward bend (Ardha
uttanasana); Triangle (Utthita trikonasana); Reverse triangle
(Parivrtta trikonasana); Downward facing dog (Adhomukha
svanasana); Marichi’s pose (Marichyasana I and III, Utthita
marichyasana); Seated twist in chair (Bharadvajasana);
One leg straight forward spinal stretch (Janu sirsasana);
Seated wide angle (Upavista konasana and Parsva upavista
konasana); Seated bound angle (Baddha konasana);
Extended legs up the wall (Urdhva prasarita padasana); Lying
down holding big toe (Supta padangusthasana); Turned
around belly (Jathara parivartanasana); Supported boat
(Navasana); Supported bridge (Setu bandha sarvangasana);
Crossed legs back arch (Supta swastikasana); Lying down
bound angle (Supta baddha konasana); Reclined mountain
(Supta tadasana); and Corpse pose (Savasana). Poses were
modified and props (blankets, chairs, and straps) used as
needed to allow participants to perform the sequences easily
and safely. Each session began with a simple yogic centering
and breathing exercise and ended with a 10–15 minute
guided supine relaxation practice (Savasana).
2.2.2. Educational Film (Control) Intervention. This stan-
dardized educational film program, described in detail
elsewhere [57], was designed to be easily replicable and to
ensure comparability of staff attention, class time, and social
interaction. Each class began with a brief meet and greet
period, followed by viewing of an educational film chosen
for its relevance and interest to our study population, then
concluded with a 10–15 minute group discussion facilitated
by a health professional with expertise in complementary
and alternative therapies and women’s health. To increase
credibility and reduce participant bias, the educational film
program was presented to potential participants as an
informative, engaging, and relaxing alternative to the yoga
classes.
2.3. Adherence and Adverse Events. Attendance at both the
yoga and the film classes was recorded by the respective
instructors. Participants in the yoga class also completed a
check sheet and log after each home practice session, indi-
cating the number of minutes practiced and any comments
they might have regarding the session. Homework logs were
turned in to the instructor at the first group class each week.
Adverse events were tracked via weekly review of par-
ticipant yoga logs. At the beginning of each class, the
yoga instructor also queried participants regarding potential
problems; these were likewise recorded. In addition, partici-
pants were encouraged to contact study investigators and/or
staff regarding any potential concerns.
2.4. Statistical Analysis. Data were analyzed using PASW
v. 18. Differences between those who did versus did not
meet criteria for RLS at baseline, and between yoga and
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control group participants at baseline were evaluated using
chi-square (for categorical variables), student independent
samples t tests (for continuous variables with a normal
distribution), or Mann-Whitney U tests (for ordinal vari-
ables or continuous variables with evidence of skewing).
Within group changes over time (pre- to postintervention)
were evaluated using chi-square or McNemar test (cate-
gorical variables), paired t tests (continuous variables), or
Wilcoxon signed rank test (ordinal or continuous vari-
ables with evidence of skewing). Between-group differences
over time were assessed using Repeated Measures ANOVA
(multivariate tests). Distributions of all dependent variables
were examined to ensure the assumptions of normality
and sphericity were met and variables transformed as
necessary. Between-group differences over time in cate-
gorical variables were assessed using logistic regression.
Effect sizes were calculated using Cohen’s d [67], with
between-group effect size adjusted for differences in baseline
values.
3. Results
Twenty (27%) of the 75 women enrolled in the parent trial
met the IRLSSG four essential diagnostic criteria for RLS,
with symptoms at least once per month (n = 10 yoga
group, 10 film group participants). Only 2 (10%) of the
20 reported having received an RLS diagnosis; neither were
taking RLS medications. Of those with RLS, 17 (8 yoga, 9
control) experienced symptoms at least once/week. Baseline
characteristics of the participants with versus without RLS
are given in Table 1. Relative to those without RLS, women
with RLS demonstrated significantly poorer sleep quality,
greater prevalence of insomnia (85% versus 38% for those
with versus without RLS, P = 0.0002), shorter sleep duration
(6.2 ± 0.3 versus 7.1 ± 0.2 hours, P = 0.002), and higher
diastolic and systolic blood pressure (P < 0.005) and were
more likely to report a history of depression (P < 0.01).
Participants with RLS were less likely to specify a history
of hormone replacement therapy (P = 0.03) and indicated
a significantly higher number of pregnancies than those
without RLS (X = 2.9 ± 0.5 versus 1.8 ± 0.2, resp., P =
0.02). Those with RLS also tended to report higher trait
anxiety, greater mood impairment, and lower vigor (P <
0.1). Women with RLS did not differ from those without RLS
in baseline ferritin levels (81± 10.5 versus 84.7± 8.4 ng/mL,
resp., P = 0.8) or in the prevalence of low ferritin levels (<
50 ng/mL, 30% versus 36%, resp., P = 0.6).
Of those 20 participants screening positive for RLS, 5
(25%) were African American, 65% had completed at least
4 years of college, 65% were employed at least part time, 35%
were married, and 50% were pre-diabetic (fasting glucose
100–125mg/dL). Participant age averaged 58.8 ± 0.9 years.
As indicated in Table 2, treatment and control groups did
not differ in demographic characteristics, or in baseline
lifestyle factors, anthropometric characteristics, medical his-
tory, health profiles, prevalence of insomnia, or reported
frequency of RLS symptoms. Mood and sleep profiles were
also similar between the groups (P > 0.3, data not shown).
Eighteen of the 20 participants with RLS completed the final
assessment (8 yoga, 10 controls). Those leaving the study
(one non-Hispanic white, one African American) dropped
out during the first 2-3 weeks due to health reasons unrelated
to the yoga program. Adherence in both the yoga and
the educational film group was very good overall. Class
attendance in the two groups was similar (mean attendance
= 13.1 ± 1.4 versus 13.6 ± 0.8 classes (of 16 total classes)
for the yoga versus film group participants, respectively,
P = 0.75). Yoga group participants completed homework
practice a mean of 4.1±0.2 days/week, with an average 28.0±
3.3 minutes/practice session. Participant feedback on open-
ended exit questionnaires was also positive, with participants
of both groups expressing enthusiasm for their respective
programs [57]. Of the 8 yoga group participants completing
the study, all cited high satisfaction with the yoga program
and all reported multiple benefits on their yoga logs and/or
exit questionnaires, including increased strength, flexibility
and mobility (N = 6), reduced pain (N = 3), enhanced
energy and well-being (N = 6), increased feelings of peace,
tranquility, and relaxation (N = 8), and greater body
awareness (N = 4). While three yoga group participants
indicated some mild, temporary muscle soreness in the
first few weeks, no participants reported significant pain,
discomfort or other adverse events in association with the
yoga program.
As illustrated in Table 3, yoga group participants showed
significant reduction over time in prevalence of insomnia
(P = 0.01) and significant improvement in sleep quality,
both overall (P = 0.001) and in the domains of sleep
duration (P = 0.02), efficiency (P = 0.01), disturbance
(P = 0.03), and daytime dysfunction (P = 0.002). Reported
average sleep duration increased from 5.7 ± 0.5 to 7.3 ± 0.5
hours (P = 0.001). Yoga participants also demonstrated
significant, or marginally significant improvements in all but
one domain of mood (P ≤ 0.08), as well as significant
reductions in state anxiety, perceived stress, and both systolic
and diastolic blood pressure (P < 0.05).
Despite limited study power, the yoga group demon-
strated significantly greater improvement than controls in
several domains of sleep quality, greater reductions in
prevalence of insomnia, and greater increases in average
sleep duration. Relative to controls, yoga group partici-
pants also showed significantly greater reductions in per-
ceived stress, mood disturbance, state anxiety, and both
systolic and diastolic blood pressure (all P’s ≤ 0.05).
Adjusted intergroup effect sizes for psychosocial variables
were large, with those for summary scores ranging from
1.9 for state anxiety to 2.6 for sleep quality (Table 3);
intergroup effect sizes for blood pressure were also sub-
stantial, calculated as 0.9 for diastolic blood pressure and
1.25 for systolic blood pressure. Intent to treat analysis,
using the conservative last value carried forward method
to address missing data, did not appreciably alter these
findings. Neither treatment expectancy scores nor change
in physical activity or social support differed significantly
between the two groups; moreover, adjustment for these
variables did not materially alter the results, suggesting that
these factors did not explain the observed between-group
differences.
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Table 2: Baseline characteristics of participants with restless legs syndrome (RLS) assigned to the yoga (N = 10) versus the educational film
(control) group (N = 10).
Treatment Group
Yoga Educational Film (control)
Frequency/Mean Percent/SE Frequency/Mean Percent/SE P
Demographic and lifestyle characteristics
Age in years (Mean, SE) 58.40 2.00 58.90 2.88 NS
Race/ethnicity NS
Non-Hispanic White 8 80.00% 7 70.00%
African American 2 20.00% 3 30.00%
Education NS
<4 years college 3 30.00% 4 40.00%
≥4 years college 7 70.00% 6 60.00%
Employed 7 70.00% 6 60.00% NS
Married/Cohabiting 4 40.00% 3 30.00% NS
Mean daily intake of the following:
Caffeine (mg) 162.68 49.93 147.77 35.74 NS
Alcohol (g) 19.57 15.91 20.42 16.38 NS
Health history
Reported history of:
High blood pressure 4 40.00% 5 50.00% NS
Depression 5 50.00% 5 50.00% NS
Anxiety 2 20.00% 3 30.00% NS
Prediabetic (fasting glucose 100–125mg/dL) 5 50.00% 5 50.00% NS
Serum ferritin levels (ng/mL) 81.40 15.35 80.56 15.32 NS
RLS symptoms NS
1–3x/month 2 20.00% 1 10.00%
At least 1x/week 8 80.00% 9 90.00%
Obese (body mass index ≥30) 6 60.00% 5 50.00% NS
Abbreviations. NS: nonsignificant (P > 0.5).
4. Discussion
RLS is a common sleep and sensorimotor disorder associated
with significant reductions in quality of life that are largely
attributable to the substantial impairment in sleep andmood
commonly accompanying RLS [4]. In light of the potentially
serious side effects of existing pharmacological treatments
for RLS, investigation of promising lifestyle and behavioral
interventions is clearly warranted. To our knowledge, this
is the first study to examine the effects of yoga in persons
with RLS, and among the few trials to examine the potential
benefits of any nonpharmacologic intervention for those
suffering from this disorder. Findings of this preliminary
RCT suggest that yoga can significantly improve sleep,
enhance mood, reduce stress and anxiety, and decrease blood
pressure in postmenopausal women with RLS, and thus
may offer a promising new treatment modality for this
population. Moreover, the overall excellent compliance, high
participant satisfaction, and lack of adverse events observed
in this study suggest that a gentle yoga program is both
feasible and acceptable to older women with RLS.
Consistent with our findings, a nonrandomized con-
trolled trial in 14 dialysis patients with RLS reported signifi-
cant improvements in sleep and mood in those completing a
16-week aerobic exercise program, with adjusted intergroup
effect sizes ranging from 0.75 to 1.00 [37]. Likewise, a pre-
post study of 25 outpatients with psychosocial impairment
due to RLS reported significant, although more modest
improvements in sleep and mood following 8 weeks of
CBT (effect sizes 0.1–0.8) [39], improvements that appeared
attributable at least in part to mindfulness, breathing, and
other stress-reduction exercises. Although no published
studies have assessed the effects of yoga on blood pressure in
RLS patients, a number of controlled studies have reported
yoga interventions to reduce blood pressure in other both
healthy and chronically ill populations [41, 49, 68–70].
While we did not assess the effects of yoga specifically on
symptoms of RLS, change in sleep and mood are endpoints
recommended for use in clinical trials by the IRLSSG [7] and
have been used in trials regarding the efficacy of dopamine
agonists and other pharmaceutical treatments for RLS [71–
76]. Of particular note, the improvements in sleep quality
and mood observed following our 8-week yoga program
appear comparable to those reported in recent pharmaceu-
tical trials that used similar measures in RLS patients [71,
72, 74, 76, 77], suggesting that yoga could possibly provide
a viable alternative to pharmaceutical therapy for some
patients. Given these promising preliminary findings, larger
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Figure 1: Possible pathways by which yoga may attenuate the distressing symptoms associated with RLS.
controlled trials are warranted to investigate the potential
utility of yoga as an adjunct or primary treatment for RLS.
Only 10% of study participants screening positive for
RLS had received a physician diagnosis, comparable to the
low diagnostic rates generally reported in other, larger studies
[78–80]. Consistent with previous research [81–83], partic-
ipants with RLS reported higher parity and demonstrated
significantly greater sleep deficits and mood disturbance
than those without RLS, with 85% indicating insomnia
at baseline and 50% reporting a history of depression. In
agreement with several, but not all recent studies [21],
RLS was associated with significantly higher blood pressure
in this study. Participants with RLS were also less likely
to report use of hormone replacement therapy (HRT)
than those without RLS. Evidence from recent experimen-
tal studies in postmenopausal women suggest HRT may
decrease complaints of restless legs [84], improve subjective
sleep quality [85, 86], suppress muscle sympathetic nerve
activity [87], and reduce nocturnal arousals [84], findings
consistent with a possible protective effect of HRT for
RLS. However, the relation between HRT and RLS remains
unclear, with 2 epidemiological studies indicating positive,
although nonsignificant, associations between RLS and HRT
[88, 89], and a French study of 440 postmenopausal women
with RLS reporting no relation of HRT use to symptom
severity [90].
Although mechanisms underlying the improvements
with yoga observed in this study remain speculative, yoga
may benefit those with RLS via several possible interrelated
pathways, illustrated in Figure 1. For example, by reducing
the activation and reactivity of the sympathetic nervous
system and the HPA axis, factors recently implicated in RLS
etiology [9, 21, 25] and known to have strong, bidirectional
relationships with sleep and mood [91, 92], yoga may atten-
uate RLS-associated pain and discomfort, reduce perceived
stress and promote feelings of well-being, enhance sleep,
lower muscle excitability, and foster positive downstream
changes in metabolic status, neuroendocrine function, and
inflammatory responses. Second, as illustrated in pathway
2, yoga may also alleviate the distressing symptoms of
RLS by directly enhancing parasympathetic output, possibly
via stimulation of the vagus nerve [93–95], and in this
way, shift the autonomic nervous system balance from
primarily sympathetic to parasympathetic [93, 95]. This, in
turn, may enhance sleep and mood, reduce perceived pain,
promote muscle relaxation, and lead to positive changes in
cardiovagal function and related neuroendocrine, metabolic,
and inflammatory responses.
Third, findings of recent neuroimaging and neurophys-
iological studies [93, 96, 97] suggest that yogic practices
may, by selectively activating specific neurochemical systems
implicated in RLS, likewise promote beneficial changes
in sympathetic/parasympathetic balance, in neuroendocrine
function, in affect, sleep, and pain processing, and in related
metabolic and inflammatory responses (pathway 3). For
example, yogic practices have been shown to increase brain
levels of dopamine [98], a neurotransmitter long implicated
in the development of RLS and thought to play a key role
in pain processing [99], sleep [100], motor control [101],
and metabolic regulation [102, 103]. Yoga also increases
GABA [97], an inhibitory neurotransmitter involved in
the regulation of muscular excitability [104], mood [105],
sleep [100], and pain processing [106]; the GABA agonist
gabapentin, an anticonvulsant used in treating RLS [73, 77],
as well as chronic pain, mood disorders, and insomnia [107–
109], is thought to operate at least in part by increasing brain
GABA [73, 77].
4.1. Strengths and Limitations. Strengths of this study include
the community-based design, randomization of participants,
between-group similarity in baseline characteristics, high
participant retention and adherence, and a comparison
condition designed to control for time, attention, and social
interaction. Limitations of this pilot study are several. Sample
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sizes were small, reducing our power to detect between-
group differences over time. However, despite limited power,
we observed significant improvement in the yoga versus
control group in several clinically important parameters,
again arguing for a potentially powerful beneficial effect
of the yoga program. Although the educational film pro-
gram was designed to control for staff attention, setting,
and class time, control group participants did not receive
homework assignments. In addition, while assessors were
blinded to participant treatment status, participants could
not be masked. However, response to the educational film
(control) program was enthusiastic, and both retention and
compliance were excellent [57]. Treatment expectancies did
not differ between-groups, and adjustment for treatment
expectancies did not materially alter findings, suggesting
that placebo effects did not explain the observed findings.
Moreover, observed effect sizes were substantially larger than
would be expected with placebo [110], and significantly
greater than those observed in the controls.
The study population was restricted to sedentary, over-
weight, postmenopausal women, and findings may therefore
not be generalizable to other populations. RLS diagnosis was
based on self-report, and some degree of diagnostic error is
thus likely. However, affirmative response to all 4 essential
criteria renders inclusion of mimics less likely [111]. Finally,
the parent study was not designed specifically to address
effects of yoga practice on RLS, and we did not measure
change in RLS symptoms per se. However, as indicated
above, we did screen for RLS at baseline and assess change
in sleep quality and mood, which are outcomes that have
been recommended for inclusion in clinical trials of RLS [7]
and often used as secondary endpoints in pharmaceutical
trials of RLS patients [112–116]. Significant sleep and mood
impairment have been repeatedly documented in studies of
RLS [7, 117, 118]. Sleep loss is the most common presenting
complaint of patients seekingmedical care for RLS [118, 119]
and is thought to explain, in large part, the negative effects of
RLS on health and quality of life [80].
5. Conclusions
These preliminary findings suggest that yoga may offer a
safe, beneficial intervention for reducing sleep and mood
disturbance, perceived stress, anxiety, and blood pressure in
older women with RLS. Larger controlled trials are needed
to confirm these benefits in this and other adult populations
with RLS, examine the effects of yoga practice specifically
on RLS symptoms and symptom severity, and to evaluate
potential underlying mechanisms.
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